



CORE BRIEF TO MANAGEMENT GROUP MEMBERS

MEETING HELD ON 25 FEBRUARY 2021

This briefing sets out the key areas of discussion and decision. It aims to ensure the Management Group members have a common core brief to disseminate within their organisation.

1. Welcome and Introductions

The Chair welcomed members to the meeting noting that, due to the COVID-19 pandemic, the meeting was being held via MS Teams. It was noted that a quorum had been achieved.

Written questions from members and answers had been published in advance of the meeting and had been embedded within the meeting papers.

2. Action Log

Members noted the action log and received an update on:

- **MG145** - Paediatric Endocrinology: Review of activity levels – carried forward to July 2021.
- **MG210** - Paediatric Ketogenic Diet – Change in Service Model: Review of activity levels – carried forward to July 2021.

3. Managing Director's Report

Members received a paper providing an update on de-escalation of the Augmentative and Alternative Communication service was taken as read.

4. All Wales Replacement Wheelchair Programme for the Posture and Mobility Service

Members received a paper that provided members with an update on the investment made for the Wheelchair Replacement Programme for the Posture and Mobility service in South and North Wales.

Members (1) noted the investment made for the replacement wheelchair programme in south and north Wales and the activity levels delivered against the plan for the All Wales Posture and Mobility Service; (2) noted the progress made to obtain a more detailed financial summary for the south Wales service of the planned and actual expenditure against the replacement programme including a robust minimum data set; and (3) received assurance that both services have a robust recovery plan to ensure delivery of the expected number of replacement wheelchairs over the three/ four year period.

5. All Wales Blueteq High Cost Drug Software Implementation Project – Progress Report

Members received a paper that provided an update on the implementation of stage 1 of the Blueteq high cost drug prescribing system across NHS Wales. Members were advised of the recent positive feedback received from both health board and Velindre pharmacy colleagues, also of their enthusiasm to extend the package to secondary care in due course.

Members noted the information presented within the report.

6. Activity Report – Month 9 2020-21

Members received a paper the purpose of which was to highlight the scale of the decrease in activity levels during the peak COVID-19 period, and whether there are any signs of recovery in specialised services activity. These activity decreases were shown in the context of the potential risk re patient harms and of the loss of value from nationally agreed financial block contract arrangements.

Members noted the information presented within the report.

7. Proposals for Utilisation of Underspend

Members received a paper that reported the WHSSC Chair's Actions taken to approve proposals for the utilisation of forecast underspend, based on the Joint Committee's decision taken on 15 December 2020.

Members noted the list of proposals supported by WHSSC Corporate Directors Group Board and approved by WHSSC Chair's Action in line with the decision of Joint Committee taken on 15 December 2020.

8. Policy Group Report

Members received a paper the purpose of which was to update them on the work of the WHSSC Policy Group during the latest quarter (November 2020 – January 2021).

Members noted the information presented within the report.

9. 2020-21 Month 10 Finance Report

Members received a paper the purpose of which was to provide the current financial position of WHSSC together with the outturn forecast for the financial year. The financial position at month 10 is a year to date underspend of £16.7m and a forecast year end under spend of £14.7m.

This under spend under spend relates mainly to months 1-10 underspend on the pass through elements of welsh provider SLA's, NHS England anticipated underperformance against agreed block contracts where provider activity is forecast at > 20% below agreed baseline and Q1 – Q3 2020-21 development slippage.

Members noted the information presented in the paper.

10. Integrated Commissioning Plan 2021-22 (ICP)

Members were advised that Joint Committee approved the ICP at its meeting on 16 February 2021 and thanked the WHSS Team and Management Group for delivering the Plan in good time.

